Pages that link to "Q59706187"
Jump to navigation
Jump to search
The following pages link to Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features (Q59706187):
Displaying 50 items.
- Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia (Q28085419) (← links)
- Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. (Q34288148) (← links)
- Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice (Q34294898) (← links)
- A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range (Q35119292) (← links)
- Day care monopolar transurethral resection of prostate: Is it feasible? (Q35394655) (← links)
- Prostate kallikrein markers in diagnosis, risk stratification and prognosis. (Q35683035) (← links)
- Prostate-specific antigen and screening for prostate cancer (Q35720552) (← links)
- Glycosylation status of serum immunoglobulin G in patients with prostate diseases. (Q35924714) (← links)
- Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden (Q35948229) (← links)
- Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. (Q36075932) (← links)
- PSA testing: an evolving relationship with prostate cancer screening (Q36325601) (← links)
- Optimizing prostate biopsy strategies for the diagnosis of prostate cancer. (Q36598343) (← links)
- Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml (Q36837061) (← links)
- Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography (Q37113204) (← links)
- The implementation of screening for prostate cancer (Q37777325) (← links)
- Prostate‐specific antigen 1.5–4.0 ng/mL: a diagnostic challenge and danger zone (Q37895342) (← links)
- Risk stratification in prostate cancer screening. (Q38068114) (← links)
- Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers (Q38084817) (← links)
- Seminal plasma as a diagnostic fluid for male reproductive system disorders (Q38202841) (← links)
- The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis (Q38215292) (← links)
- Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System (Q38922207) (← links)
- Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram (Q39476138) (← links)
- Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination (Q39645828) (← links)
- Prediction of prostate cancer in extended-field biopsies of the prostate (Q39678203) (← links)
- More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects (Q39743710) (← links)
- Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial (Q39781202) (← links)
- Prostate biopsy in subjects with abnormal transrectal ultrasonography but normal digital examination findings and prostate-specific antigen levels (Q39803592) (← links)
- Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. (Q39820627) (← links)
- Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL. (Q39925005) (← links)
- Program for prostate cancer screening using a mobile unit: results from Brazil (Q39933439) (← links)
- The effects of cigarette smoking on prostate-specific antigen in two different age groups (Q40153712) (← links)
- Outcome after radical prostatectomy in young men with or without a family history of prostate cancer (Q42685733) (← links)
- A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men. (Q42738041) (← links)
- Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer (Q42858419) (← links)
- Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL. (Q43735798) (← links)
- Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results (Q44673047) (← links)
- Prevalence of high-grade or insignificant prostate cancer in Korean men with prostate-specific antigen levels of 3.0-4.0 ng/mL. (Q45143796) (← links)
- Variable prostate-specific antigen management patterns by nonurologist providers at a tertiary care medical center (Q45881001) (← links)
- Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml (Q46064068) (← links)
- Budget impact analysis of a new prostate cancer risk index for prostate cancer detection (Q46098777) (← links)
- Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study. (Q46120030) (← links)
- Evaluation of novel formula of PSA, age, prostate volume, and race in predicting positive prostate biopsy findings (Q46583179) (← links)
- Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL. (Q46684946) (← links)
- Prostate cancer: epidemiology and health-related quality of life (Q46900318) (← links)
- The Correlation between Body Mass Index and Routine Parameters in Men Over Fifty (Q47156572) (← links)
- Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program. (Q48157760) (← links)
- Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels (Q50143816) (← links)
- Verification Bias in Screening for Prostate Cancer (Q52956163) (← links)
- Ki67 and BUBR1 May Discriminate Clinically Insignificant Prostate Cancer in the PSA Range <4 ng/ml (Q53160720) (← links)
- Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. (Q53806279) (← links)